December Warning Letters Addressed API Testing and Microbial Control
This article was originally published in The Gold Sheet
Analytical shortfalls at active pharmaceutical ingredient manufacturers around the world figured prominently in the nine drug cGMP warning letters that FDA’s center for drugs posted online in December.
You may also be interested in...
Herbalife raises full-year guidance
Foreign tablets, active pharmaceutical ingredient residues and failed line clearance plagued operations at repackers that received FDA warning letters in FY 2023.
Director of the FDA’s center for drugs slams firm for failing to reach out before suspending operations in the wake of an inspection that raised serious data integrity concerns. Instead, firms should be alerting the agency as soon as they realize there could be shortages.